TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39210299

Group type: EXPERIMENTAL
Intervention: Bipedicle vessel utilization for flap supercharge
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Superior inferior epigastric vein (SIEV) utilization
Number of subjects: 278

Group type: COMPARATOR
Intervention: SIEV as primary choice for flap supercharge (pre-MIS)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Contralateral DIEP pedicle prominence (post-MIS)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Utilization of thoracodorsal artery and lateral thoracic artery
Number of subjects: 278
Study: 39210314

Group type: EXPERIMENTAL
Intervention: START mHealth application
Number of subjects: 250

Group type: COMPARATOR
Intervention: Website with referrals to HIV care and substance use disorder treatment resources
Number of subjects: 250
Study: 39210342

Group type: EXPERIMENTAL
Intervention: Shen Que moxibustion (SQM) + IVF treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: IVF treatment alone (Control)
Number of subjects: 100
Study: 39210362

Group type: EXPERIMENTAL
Intervention: Rug-weaving plication technique (Group 1)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional colporrhaphy (Group 2)
Number of subjects: 65
Study: 39210388

Group type: EXPERIMENTAL
Intervention: GlobalConsent educational program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher-intensity implementation strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated surveys with male students
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost tracking
Number of subjects: 0
Study: 39210393

Group type: EXPERIMENTAL
Intervention: Community participatory mapping
Number of subjects: 94
Study: 39210431

Group type: EXPERIMENTAL
Intervention: salvage radiotherapy (sRT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: surveillance-only
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: initial ISUP grade 5
Number of subjects: 101
Study: 39210472

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg daily for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo daily for 3 months
Number of subjects: 100
Study: 39210606

Group type: EXPERIMENTAL
Intervention: Transthyretin amyloid cardiomyopathy
Number of subjects: 20
Study: 39210725

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 13194

Group type: COMPARATOR
Intervention: RASi (enalapril or valsartan)
Number of subjects: 13194
Study: 39210835

Group type: EXPERIMENTAL
Intervention: Zavegepant 10 mg nasal spray
Number of subjects: 603
Study: 39210941

Group type: EXPERIMENTAL
Intervention: EPI diagnosed by stool fecal elastase (FE-1) levels
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Idiopathic AP etiology
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Moderately severe or severe AP
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Baseline diabetes mellitus
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Index mild attack of AP
Number of subjects: 85
Study: 39211037

Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stromal cells (UC-MSCs)
Number of subjects: 86
Study: 39211540

Group type: EXPERIMENTAL
Intervention: Multichannel tDCS targeting the left DLPFC, 37 sessions of 30 minutes each over 8 weeks (4 weeks daily treatment + 4 weeks taper).
Number of subjects: 35
Study: 39211575

Group type: EXPERIMENTAL
Intervention: Cell Phone Support delivered by phone calls (CPS-C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cell Phone Support delivered by text messages (CPS-T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Automated text message reminders (ATR)
Number of subjects: 0
Study: 39211745

Group type: EXPERIMENTAL
Intervention: Individually tailored nutritional guidance from a clinical nutritionist and oral health guidance from a dental hygienist
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 220
Study: 39211748

Group type: EXPERIMENTAL
Intervention: TTViV implantation via femoral vein approach
Number of subjects: 6
Study: 39211865

Group type: EXPERIMENTAL
Intervention: Navtemadlin (KRT-232) 120 mg daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Navtemadlin (KRT-232) 240 mg daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Navtemadlin (KRT-232)
Number of subjects: 21
Study: 39211964

Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoid (methylprednisolone, 250 mg)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 39212045

Group type: EXPERIMENTAL
Intervention: Higher left ventricular (LV) mass index
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Higher E/average e' ratio
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Higher LV mass and volume
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Impaired right ventricular structure and function
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Composite renal outcome (≥50% decline in estimated glomerular filtration rate, development of end-stage renal disease, or death attributable to renal causes)
Number of subjects: 1097
Study: 39212246

Group type: EXPERIMENTAL
Intervention: Low-dose digoxin
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1002
Study: 39212270

Group type: EXPERIMENTAL
Intervention: Continuation of RASIs until the day of surgery (n=1107)
Number of subjects: 2222

Group type: COMPARATOR
Intervention: Discontinuation of RASIs 48 hours prior to surgery (n=1115)
Number of subjects: 2222
Study: 39212524

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Thermal dosimetry
Number of subjects: 17
Study: 39212948

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 211
Study: 39212950

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 0
Study: 39212990

Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment (immediate)
Number of subjects: 997

Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment (starting on day 8)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment (immediate) in patients with PAD
Number of subjects: 997

Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment (starting on day 8) in patients with PAD
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment (immediate) in patients without PAD
Number of subjects: 997

Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment (starting on day 8) in patients without PAD
Number of subjects: 997
Study: 39213024

Group type: EXPERIMENTAL
Intervention: Day program attendees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propensity score-matched cohort of older nonattendees
Number of subjects: 0
Study: 39213031

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 9672

Group type: EXPERIMENTAL
Intervention: Risk factors identified
Number of subjects: 9672

Group type: EXPERIMENTAL
Intervention: Subgroup analysis
Number of subjects: 9672

Group type: EXPERIMENTAL
Intervention: Urban residents
Number of subjects: 9672

Group type: EXPERIMENTAL
Intervention: eGFR ≥90 mL/min/1.73 m²
Number of subjects: 9672
Study: 39213138

Group type: EXPERIMENTAL
Intervention: Cilofexor (100 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Firsocostat (20 mg)
Number of subjects: 39
Study: 39213187

Group type: EXPERIMENTAL
Intervention: Interruption of beta-blocker treatment
Number of subjects: 3698

Group type: COMPARATOR
Intervention: Continuation of beta-blocker treatment
Number of subjects: 3698
Study: 39213194

Group type: EXPERIMENTAL
Intervention: Vutrisiran (25 mg) every 12 weeks for up to 36 months
Number of subjects: 655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study: 39213367

Group type: EXPERIMENTAL
Intervention: Optilume drug-coated balloon (DCB)
Number of subjects: 53
Study: 39213421

Group type: EXPERIMENTAL
Intervention: Magrolimab plus rituximab (M+R)
Number of subjects: 46
Study: 39213738

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Anhedonia (BATA)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both BATA and MBCT
Number of subjects: 116
Study: 39213786

Group type: EXPERIMENTAL
Intervention: Early Responders (n=43)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Late Responders (n=99)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Stable Disease (n=193)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Non-Responders (n=187)
Number of subjects: 522
Study: 39214018

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard consolidation chemotherapy (SC)
Number of subjects: 0
Study: 39214047

Group type: EXPERIMENTAL
Intervention: PF-06952229 monotherapy 375 mg, oral b.i.d., 7 days on/7 days off, 28-day cycles (Part 1A)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PF-06952229 monotherapy 375 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PF-06952229 monotherapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PF-06952229
Number of subjects: 49
Study: 39214106

Group type: EXPERIMENTAL
Intervention: Capivasertib-fulvestrant
Number of subjects: 901

Group type: COMPARATOR
Intervention: Placebo-fulvestrant
Number of subjects: 901
Study: 39214467

Group type: EXPERIMENTAL
Intervention: Bepirovirsen 300 mg once weekly for 24 weeks followed by Peg-IFN 180 μg once weekly for up to 24 weeks (Arm 1)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Bepirovirsen 300 mg once weekly for 12 weeks followed by Peg-IFN 180 μg once weekly for up to 24 weeks (Arm 2)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Sequential therapy with bepirovirsen followed by Peg-IFN
Number of subjects: 108

Group type: COMPARATOR
Intervention: Bepirovirsen alone
Number of subjects: 108
Study: 39214650

Group type: EXPERIMENTAL
Intervention: Eganelisib combined with atezolizumab and nab-paclitaxel
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Peripheral blood analyses
Number of subjects: 11
Study: 39214801

Group type: EXPERIMENTAL
Intervention: Milvexian 100 mg twice daily
Number of subjects: 15500

Group type: COMPARATOR
Intervention: Apixaban (5 mg or 2.5 mg per label indication) twice daily
Number of subjects: 15500
Study: 39214886

Group type: EXPERIMENTAL
Intervention: Nike Advanced Footwear Technology Spikes (NAS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control condition (SS)
Number of subjects: 21
Study: 39214920

Group type: EXPERIMENTAL
Intervention: Subcutaneous bermekimab 400 mg in Study 1
Number of subjects: 329

Group type: COMPARATOR
Intervention: Subcutaneous bermekimab 400 mg qw or every 2 weeks in Study 2
Number of subjects: 329

Group type: COMPARATOR
Intervention: Subcutaneous bermekimab 350 mg or 700 mg qw in GENESIS
Number of subjects: 329

Group type: COMPARATOR
Intervention: Intravenous bermekimab 800 mg qw in LUNA
Number of subjects: 329
Study: 39215063

Group type: EXPERIMENTAL
Intervention: 20 g of dark chocolate
Number of subjects: 20

Group type: COMPARATOR
Intervention: 7.5 g of milk chocolate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: dark chocolate
Number of subjects: 20

Group type: COMPARATOR
Intervention: milk chocolate
Number of subjects: 20
Study: 39215149

Group type: EXPERIMENTAL
Intervention: Behaviorally informed electronic letter-based nudges
Number of subjects: 881373

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 881373
Study: 39215196

Group type: EXPERIMENTAL
Intervention: Transepidermal water loss (TEWL)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Skin pH
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Stratum corneum hydration (SCH)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Sebum content
Number of subjects: 384
Study: 39215253

Group type: EXPERIMENTAL
Intervention: Periodontitis group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 90
Study: 39215257

Group type: EXPERIMENTAL
Intervention: Caregiving Management Needs Scale (CMNS)
Number of subjects: 250
Study: 39215274

Group type: EXPERIMENTAL
Intervention: Single Application Group (SAG) - one piezocision before canine retraction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multiple Application Group (MAG) - three piezocisions over 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (contralateral sides of both groups)
Number of subjects: 30
Study: 39215289

Group type: EXPERIMENTAL
Intervention: Stannous fluoride dentifrice (SnF)
Number of subjects: 40
Study: 39215291

Group type: EXPERIMENTAL
Intervention: Haptotherapeutic Well-Being Scale
Number of subjects: 242
Study: 39215293

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: MMP-2 and MMP-9 expression levels
Number of subjects: 63
Study: 39215301

Group type: EXPERIMENTAL
Intervention: Primary total elbow replacement (TER)
Number of subjects: 0
Study: 39215323

Group type: EXPERIMENTAL
Intervention: Hyaluronidase (150 IU)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (contralateral sides)
Number of subjects: 60
Study: 39215351

Group type: EXPERIMENTAL
Intervention: PF-06817024
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39215367

Group type: EXPERIMENTAL
Intervention: Tracheal intubation-associated cardiac arrest (TI-CA)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Non-tracheal intubation-associated cardiac arrest (non-TI-CA)
Number of subjects: 315
Study: 39215531

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (Sac/Val) therapy
Number of subjects: 376

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (control)
Number of subjects: 376
Study: 39215646

Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-Dose Quadrivalent Influenza Vaccine
Number of subjects: 0
Study: 39215793

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 160 mg orally daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Levonorgestrel-intrauterine system (LNG-IUS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both MA and LNG-IUS
Number of subjects: 36
Study: 39215812

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39215861

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 39215872

Group type: EXPERIMENTAL
Intervention: Carnosine (2 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39215949

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks (control group in BE OPTIMAL)
Number of subjects: 1032
Study: 39215959

Group type: EXPERIMENTAL
Intervention: Aspirin monotherapy
Number of subjects: 5833

Group type: COMPARATOR
Intervention: Clopidogrel monotherapy
Number of subjects: 5833
Study: 39215972

Group type: EXPERIMENTAL
Intervention: Tight potassium control (supplementing if serum potassium concentration fell below 4.5 mEq/L)
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Relaxed potassium control (supplementing if serum potassium concentration fell below 3.6 mEq/L)
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Relaxed potassium control
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: Tight potassium control
Number of subjects: 1690
Study: 39216091

Group type: EXPERIMENTAL
Intervention: High-sensitivity CRP
Number of subjects: 27939

Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 27939

Group type: EXPERIMENTAL
Intervention: Lipoprotein(a)
Number of subjects: 27939
Study: 39216093

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (intervention group)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Surgical mitral-valve repair or replacement (surgery group)
Number of subjects: 210
Study: 39216095

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 455

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 455
Study: 39216096

Group type: EXPERIMENTAL
Intervention: Continuation of oral anticoagulation
Number of subjects: 858

Group type: COMPARATOR
Intervention: Interruption of oral anticoagulation
Number of subjects: 858
Study: 39216092

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral-valve repair and guideline-recommended medical therapy (device group)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Medical therapy alone (control group)
Number of subjects: 505
Study: 39216107

Group type: EXPERIMENTAL
Intervention: Garetosmab 10 mg/kg every 4 weeks for 28 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Garetosmab
Number of subjects: 41
Study: 39216464

Group type: EXPERIMENTAL
Intervention: Adjunctive lacosamide (LCM) treatment
Number of subjects: 905
Study: 39216478

Group type: EXPERIMENTAL
Intervention: ESG401 (Trop2 antibody-drug conjugate) at a maximum tolerated dose of 16 mg/kg on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ESG401 (Trop2 antibody-drug conjugate) at therapeutically relevant doses
Number of subjects: 40
Study: 39216619

Group type: EXPERIMENTAL
Intervention: Reorientation of care (Group 1)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard care (Group 2)
Number of subjects: 165
Study: 39216726

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study: 39217247

Group type: EXPERIMENTAL
Intervention: Arm cycle ergometry training (ACET)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Body weight-supported treadmill training (BWSTT)
Number of subjects: 16
Study: 39217271

Group type: EXPERIMENTAL
Intervention: Digital consults (DCs)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 39217292

Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children - for Teachers (ICC-T) and Interaction Competencies with Children - for Parents (ICC-P)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 39217447

Group type: EXPERIMENTAL
Intervention: Aficamten
Number of subjects: 0
Study: 39217448

Group type: EXPERIMENTAL
Intervention: Early surgical aortic valve replacement (AVR)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Conservative treatment (watchful waiting)
Number of subjects: 157
Study: 39217450

Group type: EXPERIMENTAL
Intervention: mavacamten
Number of subjects: 231
Study: 39217453

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg once daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 39217504

Group type: EXPERIMENTAL
Intervention: Zibotentan (10 mg daily for 12 weeks)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 39217550

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 2255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2255
Study: 39217553

Group type: EXPERIMENTAL
Intervention: Semaglutide 1 mg once-weekly subcutaneous injection
Number of subjects: 3533

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3533
Study: 39217557

Group type: EXPERIMENTAL
Intervention: Physiology-guided complete revascularization
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Culprit-only revascularization
Number of subjects: 1445
Study: 39217556

Group type: EXPERIMENTAL
Intervention: Aficamten (5-20 mg daily for 24 weeks)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 39217559

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 17604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17604
Study: 39217563

Group type: EXPERIMENTAL
Intervention: Aficamten (5-20 mg for 24 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 39217564

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg once weekly
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1145
Study: 39217567

Group type: EXPERIMENTAL
Intervention: Semaglutide (2.4 mg once weekly)
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1145
Study: 39217565

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg once weekly
Number of subjects: 1145
Study: 39217569

Group type: EXPERIMENTAL
Intervention: Aficamten
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 39217570

Group type: EXPERIMENTAL
Intervention: GMRx2 ¼ dose (telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: GMRx2 ½ dose (telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 39217573

Group type: EXPERIMENTAL
Intervention: Aspirin monotherapy
Number of subjects: 926

Group type: COMPARATOR
Intervention: No antiplatelet therapy
Number of subjects: 926
Study: 39217577

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4795

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4795
Study: 39217605

Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors (eptifibatide or tirofiban)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Optimal medical therapy without GP IIb/IIIa inhibitors
Number of subjects: 120
Study: 39217617

Group type: EXPERIMENTAL
Intervention: BP-EES
Number of subjects: 239

Group type: COMPARATOR
Intervention: DP-EES
Number of subjects: 239
Study: 39217615

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation screening enhanced by NT-proBNP; NT-proBNP concentrations measured, single-lead ECG registered once if NT-proBNP <125 ng/L, prolonged screening if NT-proBNP ≥125 ng/L.
Number of subjects: 13905

Group type: COMPARATOR
Intervention: Control group (no screening).
Number of subjects: 13905

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation screening enhanced by NT-proBNP.
Number of subjects: 13905

Group type: EXPERIMENTAL
Intervention: Low NT-proBNP group (NT-proBNP <125 ng/L).
Number of subjects: 13905
Study: 39217777

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0